Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Fase II-onderzoek naar oncolytisch coxsackievirus A21 bij niet-resectabel melanoom
nov 2021 | Dermato-oncologie